A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder

Recruiting in Palo Alto (17 mi)

+38 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sirtsei Pharmaceuticals, Inc.

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial is testing a new treatment called SP-624 to see if it is safe and effective for adults with Major Depressive Disorder. It aims to help those who haven't found relief with usual treatments by adjusting brain chemicals related to mood.

Eligibility Criteria

Inclusion Criteria

Participants must be experiencing symptoms of Major Depressive Disorder that are causing them significant distress or impairment in social, occupational, or other important areas of functioning

Women who could potentially get pregnant and men with partners who could potentially get pregnant must not have sex or use contraception for the entire study and for at least 30 days after the last dose of the study drug.

In generally good physical health

+4 more